Eli Lilly and Company (NYSE:LLY) Shares Sold by Indiana Trust & Investment Management Co

Indiana Trust & Investment Management Co decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 30.9% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 11,825 shares of the company’s stock after selling 5,277 shares during the period. Eli Lilly and Company makes up 3.6% of Indiana Trust & Investment Management Co’s holdings, making the stock its 4th biggest holding. Indiana Trust & Investment Management Co’s holdings in Eli Lilly and Company were worth $10,476,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. Capital Planning LLC acquired a new position in shares of Eli Lilly and Company during the first quarter valued at $262,000. CHURCHILL MANAGEMENT Corp bought a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $6,916,000. M&G Plc acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $8,896,000. Bath Savings Trust Co raised its stake in shares of Eli Lilly and Company by 0.4% during the first quarter. Bath Savings Trust Co now owns 21,640 shares of the company’s stock worth $16,835,000 after buying an additional 76 shares during the last quarter. Finally, BTC Capital Management Inc. acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $1,432,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.1 %

Eli Lilly and Company stock traded up $0.89 during midday trading on Wednesday, reaching $914.21. The stock had a trading volume of 657,046 shares, compared to its average volume of 2,986,872. The stock has a market capitalization of $868.87 billion, a P/E ratio of 133.65, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The firm’s fifty day simple moving average is $916.37 and its 200-day simple moving average is $855.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analyst Ratings Changes

LLY has been the subject of several recent research reports. Barclays upped their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. BMO Capital Markets upped their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Morgan Stanley restated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $979.29.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.